{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:39:31Z","timestamp":1794364771785,"version":"4.9.0"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Subasumstat (TAK-981) is a first-in-class inhibitor of SUMOylation that can engage innate and adaptive immune responses in tumors by enhancing type I IFN (IFNI) production. We conducted a phase I\/II dose-escalation\/-expansion study (NCT03648372) to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of subasumstat as a single agent in patients with advanced\/metastatic solid tumors and relapsed\/refractory hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible patients received subasumstat intravenously at escalating doses twice weekly (days 1, 4, 8, and 11) or once weekly (days 1 and 8) in 21-day cycles until disease progression or unacceptable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 109 patients were enrolled (solid tumors: n = 100; lymphomas, n = 9). In phase I, four patients reported dose-limiting toxicities of grade 3 alanine transaminase\/aspartate transaminase elevation, pneumonitis, stomatitis, and cognitive disorder; 120 mg twice weekly was determined as the MTD. The most common adverse events were fatigue (47%), nausea (41%), diarrhea (36%), and pyrexia (36%). Pharmacodynamic analyses demonstrated target engagement and SUMOylation pathway inhibition, induction of an IFNI-regulated gene signature and cytokine production, and activation of innate and adaptive immune cells. Based on safety, pharmacokinetic, and pharmacodynamic findings, 90 mg twice weekly was proposed as the recommended phase II dosage. Overall, three and 26 patients achieved a partial response and stable disease, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Subasumstat had a manageable safety profile, with evidence of innate and adaptive immune response engagement in patients with advanced\/metastatic solid tumors and relapsed\/refractory hematologic malignancies. Further studies are needed to determine the role of subasumstat in cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Identification of novel and effective therapies for patients who become refractory to standard anticancer treatments remains paramount. In this phase I\/II study, subasumstat, a first-in-class SUMOylation inhibitor, had preliminary clinical activity and demonstrated target engagement, upregulation of IFN and plasma cytokines, and activation of innate and adaptive immune cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0243","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:42:42Z","timestamp":1761324162000},"page":"2025-2038","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced\/Metastatic Solid Tumors or Relapsed\/Refractory Hematologic Malignancies"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-7704","authenticated-orcid":false,"given":"Dejan","family":"Juric","sequence":"first","affiliation":[{"name":"1Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7229-4085","authenticated-orcid":false,"given":"Daniel","family":"Anderson","sequence":"additional","affiliation":[{"name":"2HealthPartners Oncology, HealthPartners Institute, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-6839","authenticated-orcid":false,"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"4Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-178X","authenticated-orcid":false,"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"5Centre for Excellence in Precision Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-0777","authenticated-orcid":false,"given":"S\u0142awomir","family":"Ma\u0144dziuk","sequence":"additional","affiliation":[{"name":"6Medical University of Lublin, Lublin, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-5554","authenticated-orcid":false,"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"7Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"Feng Jung Sherida H.","family":"Woei-A-Jin","sequence":"additional","affiliation":[{"name":"8Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-810X","authenticated-orcid":false,"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"9Hematology Department, CHU UCL Namur, Yvoir, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-4532","authenticated-orcid":false,"given":"Joanna G\u00f3ra","family":"Tybor","sequence":"additional","affiliation":[{"name":"10Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"11Hematology Department, Infanta Leonor University Hospital, Complutense University, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"12WIN Consortium for Precision Medicine, Chevilly-Larue, France."},{"name":"13Medical College of Wisconsin, Milwaukee, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8381","authenticated-orcid":false,"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[{"name":"14Hematology Department, Hospital Clinic Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9588-0415","authenticated-orcid":false,"given":"David","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"15Medical Oncology Department, Grand H\u00f4pital de Charleroi, Charleroi, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-6422","authenticated-orcid":false,"given":"Rafal","family":"Stec","sequence":"additional","affiliation":[{"name":"16Department of Oncology, Warsaw Medical University, Warsaw, Poland."},{"name":"17Biokinetica, J\u00f3zef\u00f3w, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-2005","authenticated-orcid":false,"given":"Allison","family":"Berger","sequence":"additional","affiliation":[{"name":"18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0627-8033","authenticated-orcid":false,"given":"Bo","family":"Chao","sequence":"additional","affiliation":[{"name":"19Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4961-5291","authenticated-orcid":false,"given":"Aleksander","family":"Chudnovsky","sequence":"additional","affiliation":[{"name":"20Oncology Clinical Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-7318","authenticated-orcid":false,"given":"John P.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-391X","authenticated-orcid":false,"given":"Tao","family":"Long","sequence":"additional","affiliation":[{"name":"21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7359-1560","authenticated-orcid":false,"given":"Dina","family":"Stroopinsky","sequence":"additional","affiliation":[{"name":"18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0291-1840","authenticated-orcid":false,"given":"Qi","family":"Dong","sequence":"additional","affiliation":[{"name":"22Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-5898","authenticated-orcid":false,"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[{"name":"23Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025111902054867100_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrm2293","article-title":"Concepts in sumoylation: a decade on","volume":"8","author":"Geiss-Friedlander","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025111902054867100_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ni.3342","article-title":"Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing","volume":"17","author":"Decque","year":"2016","journal-title":"Nat Immunol"},{"key":"2025111902054867100_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.biochem.73.011303.074118","article-title":"Protein modification by SUMO","volume":"73","author":"Johnson","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"2025111902054867100_bib4","first-page":"140","article-title":"High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer","volume":"5","author":"Shao","year":"2014","journal-title":"Am J Cancer Res"},{"key":"2025111902054867100_bib5","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1002\/jcp.30143","article-title":"The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications","volume":"236","author":"Zhao","year":"2021","journal-title":"J Cell Physiol"},{"key":"2025111902054867100_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5732\/cjc.011.10084","article-title":"Ubc9 expression predicts chemoresistance in breast cancer","volume":"30","author":"Chen","year":"2011","journal-title":"Chin J Cancer"},{"key":"2025111902054867100_bib7","doi-asserted-by":"crossref","first-page":"1094588","DOI":"10.3389\/fcell.2023.1094588","article-title":"SUMOylation patterns and signature characterize the tumor microenvironment and predict prognosis in lung adenocarcinoma","volume":"11","author":"Chen","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2025111902054867100_bib8","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.2174\/0929867327666200810135039","article-title":"Current status of SUMOylation inhibitors","volume":"28","author":"Brackett","year":"2021","journal-title":"Curr Med Chem"},{"key":"2025111902054867100_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","article-title":"Signalling mechanisms and cellular functions of SUMO","volume":"23","author":"Vertegaal","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025111902054867100_bib10","doi-asserted-by":"crossref","first-page":"20308","DOI":"10.18632\/aging.103804","article-title":"TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma","volume":"12","author":"Liu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2025111902054867100_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41392-023-01685-0","article-title":"SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer","volume":"8","author":"Diao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025111902054867100_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12672-025-02614-z","article-title":"SUMOylation-regulated genes in colon cancer: expression patterns and clinical implications","volume":"16","author":"Peng","year":"2025","journal-title":"Discover Oncol"},{"key":"2025111902054867100_bib13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/gutjnl-2018-317856","article-title":"SUMO pathway inhibition targets an aggressive pancreatic cancer subtype","volume":"69","author":"Biederst\u00e4dt","year":"2020","journal-title":"Gut"},{"key":"2025111902054867100_bib14","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","article-title":"Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer","volume":"64","author":"Langston","year":"2021","journal-title":"J Med Chem"},{"key":"2025111902054867100_bib15","doi-asserted-by":"crossref","first-page":"eaba7791","DOI":"10.1126\/scitranslmed.aba7791","article-title":"A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models","volume":"13","author":"Lightcap","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025111902054867100_bib16","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.2021014267","article-title":"The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation","volume":"139","author":"Nakamura","year":"2022","journal-title":"Blood"},{"key":"2025111902054867100_bib17","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","article-title":"Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model","volume":"71","author":"Kumar","year":"2022","journal-title":"Gut"},{"issue":"Suppl 16","key":"2025111902054867100_bib18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.2022.40.16_suppl.2506","article-title":"A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors","volume":"40","author":"Goel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025111902054867100_bib19","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1182\/blood-2021-152225","article-title":"TAK-981, a first-in-class SUMO-activating enzyme inhibitor, combined with rituximab in adult patients (Pts) with CD20-positive relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): phase 1 data","volume":"138","author":"Assouline","year":"2021","journal-title":"Blood"},{"key":"2025111902054867100_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025111902054867100_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025111902054867100_bib22","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1158\/1078-0432.CCR-23-0827","article-title":"Trackable intratumor microdosing and spatial profiling provide early insights into activity of investigational agents in the intact tumor microenvironment","volume":"29","author":"Derry","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025111902054867100_bib23","doi-asserted-by":"crossref","first-page":"LB318","DOI":"10.1158\/1538-7445.AM2023-LB318","article-title":"Abstract LB318: SB-4826, a first-in-class oral, covalent inhibitor of SUMO E1 that induces IFN signaling and inhibits tumor growth as monotherapy and in combination with immune checkpoint blockade","volume":"83(Suppl 8)","author":"Canon","year":"2023","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0243\/3665428\/crc-25-0243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2025\/3671817\/crc-25-0243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2025\/3671817\/crc-25-0243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:06:01Z","timestamp":1763535961000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/11\/2025\/767310\/A-First-In-Human-Study-of-the-SUMOylation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0243","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30655270","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655288","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655264","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655276","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655294","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655282","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655279","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655312","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655324","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655306","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655291","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655300","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655267","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655297","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655285","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655273","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655309","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655303","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30655327","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8156191","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}